Frontlight ResearchEarly access
CompletedPhase 2
Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
Key facts
- Who runs it
- Crinetics Pharmaceuticals Inc.
- Where
- Ann Arbor, Cleveland, East Providence, Minneapolis, Morehead City, Pasadena, Philadelphia, and St Louis, United StatesSee the 8 sitesAlso in 6 other countries, 17 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 38 people enrolled
- Started
- 3 Jul 2023
- Ended
- 22 Aug 2025
- Type of study
- Interventional
- Treatments tested
- atumelnant (CRN04894)
- Record updated
- 10 September 2026
Who can take part
- Age
- 16 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Male or female participants ≥18 to 75 years of age at the time of signing the Informed Consent Form (ICF). Participants ≥16 years of age may be included in sites located in the United States
- Classic 21-hydroxylase deficiency
- On a stable regimen of glucocorticoid replacement (eg, hydrocortisone, prednisolone, prednisone, methylprednisolone)
- Compliance with glucocorticoid replacement and mineralocorticoid replacement (if applicable) regimen during the Screening Period
- Minimum total daily dose of ≥15 mg hydrocortisone (or equivalent). For Cohort 4, a mean daily dose of ≥11 mg/m²/day of hydrocortisone or hydrocortisone equivalents will be used for inclusion
- If on estrogen therapy (any route), dose must be stable for at least 3 months prior to Screening
Who cannot take part
- Dexamethasone use within 30 days of Screening for Cohorts 1-3. In Cohort 4, dexamethasone is permitted
- History of major surgery/surgical therapy for any cause within 4 weeks prior to Screening
- Diabetes mellitus treated with insulin for less than 6 weeks prior to Screening, or with change in total daily insulin dose by >15% within 6 weeks prior to Screening
- Participants with hypothyroidism who are not receiving adequate hormone replacement therapy based on thyroid hormone levels measured at the time of Screening
- History of unstable angina or acute myocardial infarction within 12 weeks prior to Screening or other clinically significant cardiac disease at the time of Screening
- Use of antiandrogen therapy in the past 3 months (eg, spironolactone, finasteride, cyproterone acetate, flutamide)
- Use of testosterone, androgen-containing supplements, aromatase inhibitors, or growth hormone
- History of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy
- Clinically significant unstable medical condition or chronic disease other than CAH
- History of cancer excluding cured/treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ
- Known history of illicit drug or alcohol abuse within the last year
- Poorly controlled diabetes mellitus defined as having a hemoglobin A1c (HbA1c) ≥8.5%(≥69 mmol/mL), or estimated HbA1c based on fructosamine if HbA1c is not evaluable (eg, due to hemoglobinopathies)
- Diagnosis of any other form of CAH other than classic 21-hydroxylase deficiency
- Night shift workers or any other reason for abnormal sleep/wake cycles
- Pregnant or lactating
Where in United States
Also in 6 other countries, 17 sites
- Ann Arbor, MichiganHospital not named in the registry
- Cleveland, OhioHospital not named in the registry
- East Providence, Rhode IslandHospital not named in the registry
- Minneapolis, MinnesotaHospital not named in the registry
- Morehead City, North CarolinaHospital not named in the registry
- Pasadena, CaliforniaHospital not named in the registry
- Philadelphia, PennsylvaniaHospital not named in the registry
- St Louis, MissouriHospital not named in the registry
About the trial
What the trial wants to find out
The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of atumelnant (CRN04894) in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.
The group in the trial
- Sequential DoseTreatment being tested
Sequential, open-label, 12-week fixed-dose cohorts.
Treatment: atumelnant (CRN04894)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
- Record updated
- 10 September 2026